Leading Supplement Retailer Features NIAGEN® as Their Hot Ingredient for Fall, 2016
September 22 2016 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health,
wellness and nutritional ingredients that creates science-based
solutions to dietary supplement, food and beverage, skin care,
sports nutrition, and pharmaceutical products, announced leading
supplement retailer, Vitamin Shoppe, featured NIAGEN® nicotinamide
riboside (NR) in their Hot Ingredient Spotlight section in the Fall
2016 print edition of their Amazing Wellness magazine.
ChromaDex founder and CEO, Frank Jaksch, Jr. commented, “As the
aging population continues to grow, their interest in what can be
done to rediscover that sense of vitality or youthful energy grows.
The scientific evidence validating NR’s ability to increase
cellular NAD+, has people interested and wanting to learn more.”
Jaksch continued, “This type of coverage is a perfect
complement to the ongoing consumer outreach we are doing to help
people understand that the answer lies within their own cells.”
About ChromaDex:ChromaDex
leverages its complementary business units to discover, acquire,
develop and commercialize patented and proprietary ingredient
technologies that address the dietary supplement, food, beverage,
skin care and pharmaceutical markets. In addition to our ingredient
technologies unit, we also have business units focused on natural
product fine chemicals (known as "phytochemicals"), chemistry and
analytical testing services, and product regulatory and safety
consulting (known as Spherix Consulting). As a result of our
relationships with leading universities and research institutions,
we are able to discover and license early stage, IP-backed
ingredient technologies. We then utilize our in-house chemistry,
regulatory and safety consulting business units to develop
commercially viable ingredients. Our ingredient portfolio is backed
with clinical and scientific research, as well as extensive IP
protection. Our portfolio of patented ingredient technologies
includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene;
PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a
spirulina extract; and AnthOrigin™, anthocyanins derived from a
domestically-produced, water-extracted purple corn. To learn more
about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended January 2, 2016, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024